Seaport Therapeutics
Developing novel therapeutics to restore gut lymphatic function.
About
Seaport Therapeutics is a biotechnology company focused on developing novel therapeutics that restore gut lymphatic function. Their lead candidate, GlyphCeleâ„¢, is the first oral therapeutic designed for this purpose and has received significant funding from ARPA-H to advance its development. Teams look it up for Biotechnology, Pharmaceuticals, HealthTech.
Frequently asked
What does Seaport Therapeutics do?
Seaport Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, HealthTech. It is based in Cambridge, Massachusetts, USA and was founded in 2021. Public records show about 64 people and $340M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Seaport Therapeutics raised?
Seaport Therapeutics has raised a total of $340M in funding. The most recent round on record is Unknown.
Where is Seaport Therapeutics headquartered?
Seaport Therapeutics is headquartered in Cambridge, Massachusetts, USA.
When was Seaport Therapeutics founded?
Seaport Therapeutics was founded in 2021.
What industry does Seaport Therapeutics operate in?
Seaport Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech.
How many employees does Seaport Therapeutics have?
Seaport Therapeutics has approximately 64 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.